Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. - Test2 - elhamkhani - TriplyDB

Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity.

Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity.

http://www.wikidata.org/entity/Q44078720

about

Emollients and moisturisers for eczema Hygiene and emollient interventions for maintaining skin integrity in older people in hospital and residential care settings Consensus Conference on Clinical Management of pediatric Atopic Dermatitis The objective severity assessment of atopic dermatitis (OSAAD) score: validity, reliability and sensitivity in adult patients with atopic dermatitis Tmem79/Matt is the matted mouse gene and is a predisposing gene for atopic dermatitis in human subjects Potential Applications of Phyto-Derived Ceramides in Improving Epidermal Barrier Function.Murine atopic dermatitis responds to peroxisome proliferator-activated receptors alpha and beta/delta (but not gamma) and liver X receptor activators.Skin barrier function Abnormal skin barrier in the etiopathogenesis of atopic dermatitis.Research statistics in atopic eczema: what disease is this?Immunomodulatory effect of water soluble extract separated from mycelium of Phellinus linteus on experimental atopic dermatitis.[Efficacy of barrier creams in comparison to skin care products in dental laboratory technicians--a controlled trial].Thematic review series: skin lipids. The role of epidermal lipids in cutaneous permeability barrier homeostasis.Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies.Efficacy of combined peroxisome proliferator-activated receptor-α ligand and glucocorticoid therapy in a murine model of atopic dermatitis.The clinical relevance of maintaining the functional integrity of the stratum corneum in both healthy and disease-affected skin.Spot-on skin lipid complex as an adjunct therapy in dogs with atopic dermatitis: an open pilot study Expression of epidermal CAMP changes in parallel with permeability barrier status.An emerging role for the lipid mediator sphingosine-1-phosphate in mast cell effector function and allergic disease.Guidelines of care for the management of atopic dermatitis: Section 4. Prevention of disease flares and use of adjunctive therapies and approaches Stratum corneum maturation. A review of neonatal skin function.New insights into atopic dermatitis.New advances on the functions of epidermal growth factor receptor and ceramides in skin cell differentiation, disorders and cancers.Focal adhesion kinase controls pH-dependent epidermal barrier homeostasis by regulating actin-directed Na+/H+ exchanger 1 plasma membrane localization.Stratum corneum defensive functions: an integrated view.The management of dry skin with topical emollients--recent perspectives.The clinical benefit of moisturizers.Increase in short-chain ceramides correlates with an altered lipid organization and decreased barrier function in atopic eczema patients Atopic dermatitis prevention.Atopic xerosis: employment of noninvasive biophysical instrumentation for the functional analyses of the mildly abnormal stratum corneum and for the efficacy assessment of skin care products.On the effects of topical synthetic pseudoceramides: comparison of possible keratinocyte toxicities provoked by the pseudoceramides, PC104 and BIO391, and natural ceramides Comparison of the Efficacy of Atopalm(®) Multi-Lamellar Emulsion Cream and Physiogel(®) Intensive Cream in Improving Epidermal Permeability Barrier in Sensitive Skin Acceptability and efficacy of an emollient containing ceramide-precursor lipids and moisturizing factors for atopic dermatitis in pediatric patients.Clinical use of a ceramide-based moisturizer for treating dogs with atopic dermatitis.Management of itch in atopic dermatitis.Barrier repair trumps immunology in the pathogenesis and therapy of atopic dermatitis Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms "Outside-to-inside" (and now back to "outside") pathogenic mechanisms in atopic dermatitis.Co-regulation and interdependence of the mammalian epidermal permeability and antimicrobial barriers.Characterization of a hapten-induced, murine model with multiple features of atopic dermatitis: structural, immunologic, and biochemical changes following single versus multiple oxazolone challenges.

P2860

Q24186075-2F03D7CD-0CAC-4B7C-B0C7-B46916A9F875 Q24187705-1AD8F2AE-23F7-4AEE-BF7C-D460B55D6136 Q28071974-4EBFFFE3-A9A8-44AD-9A6D-0F7CB64C6E0D Q28273743-9BFEA932-A7F3-4D97-B8A4-96FAE6C59C37 Q28511427-531682CF-F1D7-4DD4-AF15-AF975E622F5C Q30313257-58E68FE8-6448-4620-827D-2EE9D97F5A20 Q30494234-D601931C-EB45-46E0-A755-74473978FD3D Q33744906-F85FEBB8-EADB-4509-9DA9-967F80E8743C Q33779047-C9FD1DAE-FB71-4D1B-AA41-CDD3433B2CBC Q34298225-57CE87F7-BE68-4119-9AC1-AFE3B4C8423C Q34417644-F7DF52DB-72DC-47FF-8FE0-1FD9C68F1519 Q34468587-3BAB9811-0D72-49E9-9BCC-B91CF4A70D72 Q34687966-F06B51AE-8BA1-40EE-B0F4-2006E647D994 Q35077866-238FE77D-F600-45B6-BB1E-67E80C0EBDC9 Q35167249-EB9EF6B3-88CF-4B10-8219-C909FAC6C1D9 Q35220452-46166D43-8B7A-49DB-ABFD-85AB02BF59B0 Q35239179-34AEE81F-7B66-49B8-9842-75086AA6EF9F Q35349520-97E6D169-B66B-410B-B178-72FD1E950B1B Q35545433-5BB66768-610C-493F-A4EB-234A1705E095 Q35603170-E9FB89C8-5B2F-4D91-8298-C93FC0A7B0DA Q35672070-9B97A80D-3FBB-47C3-BC85-54A62F8948BF Q35678332-61DD3BBA-98C0-4D94-8CD6-B02920AA199C Q35838744-E1B7777F-B32C-4E0C-9434-847A80268DD4 Q35855529-9AF59F79-C344-47FE-B372-342837010C52 Q36228049-0BE4C170-C4E0-49B9-BADD-15AA6C457F7C Q36272156-1B7293BA-F73D-4823-A734-3A615774E91A Q36305888-D3967133-7A81-4125-9836-C1B643A49023 Q36387203-653C7D8E-14D1-447B-92F5-76E459448631 Q36466794-A46EDECF-C480-490B-851D-03198D4753C9 Q36686119-27B1340B-0659-497B-AB62-EBA8CF15C69D Q36696383-58C9CFBB-7AD4-4191-974E-B3F6825992FB Q36703830-E559F2FD-870A-46E7-9B73-DB6330E6E39B Q36767733-0CC6AB0E-3280-433B-AAAC-9B4E43053248 Q36958942-E302BBC4-0342-4E0F-AFF8-EC27500CA8F4 Q36991444-A86E8CBD-09AD-4CB9-BD1A-DFD938F29618 Q37037943-1C076540-D334-4847-B7C0-BA4B690BEF20 Q37105441-C3802B1B-9D4B-42AA-ADC0-C787C3AD8A48 Q37137538-05B9ED2F-1FF9-4556-9193-7C6C0519E08F Q37164058-582DB13F-4E8D-4090-8492-70630AB70229 Q37164077-238396FE-CAA5-4325-BBB5-EF76157AE18B

P2860

Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity.

http://www.wikidata.org/entity/Q44078720

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh

2002年學術文章

@zh-hant

name

Ceramide-dominant barrier repa ...... indicator of disease activity.

@en

Ceramide-dominant barrier repa ...... indicator of disease activity.

@nl

type

label

Ceramide-dominant barrier repa ...... indicator of disease activity.

@en

Ceramide-dominant barrier repa ...... indicator of disease activity.

@nl

prefLabel

Ceramide-dominant barrier repa ...... indicator of disease activity.

@en

Ceramide-dominant barrier repa ...... indicator of disease activity.

@nl

P1433

Q44078720-DB5414AE-3DD8-420E-AFA8-2BC4C8AADD32

P1476

Q44078720-21FC423C-41C3-41A2-874C-AC94F8EDBECA

P2093

Q44078720-68E5C0F6-1459-4013-9881-01E7A769ABE5

Q44078720-98C02691-C226-44E7-ABF7-3960559D840B

Q44078720-9DB78178-AFE1-4353-BCEE-F835176A81DC

Q44078720-C7C5DCBB-EF1B-4C5C-92EF-A3BD1F2454B2

Q44078720-C816DC63-4EC6-4BEA-810B-8B25A6252209

Q44078720-E9D99120-E379-44E6-947C-3A71713C9773

Q44078720-F4C47B5F-34E1-4610-B94E-47AC524B599D

P304

Q44078720-788BBC54-E96A-4E4B-AC05-AB8C65FE42DC

P31

Q44078720-212FF116-7B20-4A41-A7E4-9C4D50388D1E

P356

Q44078720-C56F8133-90EB-462D-ADC7-D196B64EE4FD

P407

Q44078720-4B291C11-6214-4192-83E9-C58E3790C7A1

P433

Q44078720-2A15B5DD-084B-48E6-A5BE-D9D477D08A6A

P478

Q44078720-B03E3F7C-5245-47F9-9B2A-41B00D1A506A

P50

Q44078720-1FFE4EAD-1041-4FFC-90B0-689D6E640A08

P577

Q44078720-CED13C86-70AF-4AE3-90CB-1149110C57B2

P698

Q44078720-54322BF0-1E08-45FE-8E61-B4EC16C9E777

P356

MJD.2002.124617

P1433

Journal of the American Academy of Dermatology

P1476

Ceramide-dominant barrier repa ...... indicator of disease activity.

@en

P2093

Ashley J Fowler

http://www.w3.org/2001/XMLSchema#string

Jack Kao

http://www.w3.org/2001/XMLSchema#string

Joachim W Fluhr

http://www.w3.org/2001/XMLSchema#string

Mary L Williams

http://www.w3.org/2001/XMLSchema#string

Mary Y Sheu

http://www.w3.org/2001/XMLSchema#string

Peter M Elias

http://www.w3.org/2001/XMLSchema#string

Sarah L Chamlin

http://www.w3.org/2001/XMLSchema#string

P304

198-208

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1067/MJD.2002.124617

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P50

Ilona J. Frieden

P577

2002-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12140465

http://www.w3.org/2001/XMLSchema#string